Search Results - robert+sarnovsky

2 Results

Sort By:

Summary: The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR. Description of Technology: Epidermal growth factor receptor (EGFR) is a well-known oncogenic driver in lung cancer, head and neck cancer, glioblastoma multiforme (GBM) and other cancers. NCI inventors have...

Published: 2/5/2026 | Inventor(s): David Fitzgerald, Antonella Antignani, Robert Sarnovsky

Keywords(s):

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

EGFRvIII Antibodies for the Treatment of Human Cancer

Abstract: Epidermal growth factor receptor variant III (EGFRvIII) is a variant of EGFR that is an excellent target for immunotherapy because of its expression in cancer cells and not in normal cells. Inventors from the National Cancer Institute (NCI) have isolated seven mouse monoclonal antibodies that bind to the human EGFRvIII but not wildtype EGFR....

Published: 4/22/2025 | Inventor(s): David Fitzgerald, Antonella Antignani, Eric Ho, Robert Sarnovsky

Keywords(s): ADC, Antibody-drug Conjugate, CAR, chimeric antigen receptor, EGFR, EGFRvIII, Epidermal Growth Factor Receptor, Epidermal growth factor receptor variant III, FitzGerald, Recombinant Immunotoxins, RITs

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing